MedTrace Logo

Preventing Tolerance to Oxymetazoline in Allergic Rhinitis

NCT00846326 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-10-25

No results posted yet for this study

Summary

The investigators wish to evaluate the effects of decongestants like oxymetazoline and the lessening of this effect with time called 'tolerance'. The investigators will demonstrate a reversal of this tolerance with nasal steroids i.e. the investigators will show that nasal steroids protect against tolerance. This will tell us more on how the investigators can make this treatment effective and safe for patients suffering with allergic rhinitis.

Conditions

  • Allergic Rhinitis
  • Tachyphylaxis
  • Rhinitis Medicamentosa

Interventions

DRUG

oxymetazoline-fluticasone propionate

Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily

DRUG

Oxymetazoline

oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily

Sponsors & Collaborators

  • Brian J Lipworth

    lead OTHER

Principal Investigators

  • Brian Lipworth, MD, FRCP · University of Dundee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846326 on ClinicalTrials.gov